Clinical Trials Logo

Superficial Basal Cell Carcinoma clinical trials

View clinical trials related to Superficial Basal Cell Carcinoma.

Filter by:

NCT ID: NCT05713760 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Start date: April 17, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).

NCT ID: NCT05628714 Completed - Clinical trials for Superficial Basal Cell Carcinoma

A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

A patient decision aid (PDA) was tested in a population of patients with superficial basal cell carcinoma. This study evaluates whether the use of a PDA improved outcomes like decisional conflict and knowledge.

NCT ID: NCT05381597 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Start date: October 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis). 5-Fluorouracil cream is currently FDA approved for the treatment of superficial basal cell carcinoma and is routinely used by dermatologists across the country and at Boston Medical Center (BMC) for SCCis. The normal treatment regimen is 4 weeks of the 5-fluorouracil cream for both skin cancers. The application of a compounded cream consisting of 1:1 ratio 5-fluorouracil with calcipotriene will be tested. This combination cream has been shown to clear pre-skin cancers called actinic keratoses and prevent future skin cancers from developing. This combination cream for 7-14 days to see if this shorter treatment course provides clearance of the 2 types of skin cancer. This combination cream is successfully used in this manner to treat other subtypes of related skin cancers. This will be a pilot study with The primary endpoint for this pilot randomized single blinded clinical trial will be the response to treatment (yes versus no). The lesions will be assessed clinically for clearance of cancer, as would normally be done and is consistent with how comparable studies have assessed clearance. Participants will be followed closely afterwards for three years with visits at 6 months, which does not vary from standard practice. If the lesions are not clear of cancer or equivocal clinically, the lesions will be re-biopsied and normal standard of care procedure will take place.

NCT ID: NCT05157763 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Start date: June 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.

NCT ID: NCT04744935 Recruiting - Clinical trials for Basal Cell Carcinoma

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Start date: January 13, 2021
Phase: N/A
Study type: Interventional

Optical coherence tomography guided laser treatment of basal cell carcinoma

NCT ID: NCT04552990 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.

NCT ID: NCT04470726 Completed - Clinical trials for Superficial Basal Cell Carcinoma

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Start date: August 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate safety and efficacy of AIV001 treatment on low-risk basal cell carcinoma.

NCT ID: NCT03573401 Active, not recruiting - Clinical trials for Superficial Basal Cell Carcinoma

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Start date: September 25, 2018
Phase: Phase 3
Study type: Interventional

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).

NCT ID: NCT03012009 Completed - Clinical trials for Superficial Basal Cell Carcinoma

Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial

Start date: September 2014
Phase: N/A
Study type: Interventional

Photodynamic therapy (PDT) is a well established treatment option for superficial non melanoma skin cancer, such as superficial basal cell carcinoma (sBCC) and Bowen Disease (BD). However, a limited uptake of the topically applied photosensitizer methyl aminolevulinate (MAL) may reduce its efficacy. Pretreatment with an ablative carbon dioxide (CO2) laser has recently been studied in order to enhance the skin penetration of this photosensitizer. This study compares the results of a full ablative and a fractional ablative CO2 laser mode as pretreatment of PDT in the management of sBCC and BD. The endpoints efficacy, pain, aesthetics and patient preference are investigated during twelve months of follow up.

NCT ID: NCT02270645 Completed - Clinical trials for Superficial Basal Cell Carcinoma

Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser

BCC
Start date: October 2014
Phase: N/A
Study type: Interventional

Laser therapy for basal cell carcinoma may be a superior option for patients who do not wish to or cannot tolerate other treatment modalities such as topical chemotherapeutics or surgery. In this pilot study, we will preliminarily assess the efficacy and safety of the 595/1064 nm Multiplex laser when treating superficial and nodular basal cell carcinomas less than 1.5 cm in size. This is an unblinded study in which patients will be randomized to either a treatment arm or a control arm. Patients in the treatment arm will receive three treatments with the 595/1064 nm multiplex laser spaced four weeks apart. The control group will visit the clinic with the same schedule as the treatment group for monitoring of the lesion. All patients will return one month after last treatment session or clinical visit, for evaluation of clinical and histological clearance.